Literature DB >> 1993164

Characteristics of a 95-kDa matrix metalloproteinase produced by mammary carcinoma cells.

J G Lyons1, B Birkedal-Hansen, W G Moore, R L O'Grady, H Birkedal-Hansen.   

Abstract

A Mr 95,000 matrix metalloproteinase (MMP) produced by rat mammary carcinoma cells has been isolated and characterized. The MMP was secreted in a proteolytically inactive form that was free from bound tissue inhibitor of metalloproteinases. The enzyme was highly glycosylated as evident from an apparent drop of Mr from 95,000 to 83,000 after treatment with N-glycanase. Rotary shadowing electron micrographs of purified proenzyme preparations revealed a uniform set of ellipsoidal molecules. Treatment of the proenzyme with 1% SDS resulted in generation of catalytic activity and exposed a cryptic unpaired Cys residue. The latent proenzyme may be activated in at least three additional ways: either spontaneously upon storage, by treatment with organomercurials, or by limited proteolysis by trypsin. Each mode of activation yielded a distinct pattern of cleavage of the enzyme. The activated enzyme cleaved gelatin (denatured type I collagen) and native type IV and V collagen at 30-37 degrees C. Noncollagenous proteins including alpha 1-proteinase inhibitor, casein, and fibrinogen also were cleaved. The rat mammary carcinoma cell line that produces the Mr 95,000 MMP is composed of two distinct (epithelial- and myoepithelial-like) cell types. The enzyme is expressed constitutively by the epithelial cells. This suggests that expression of the Mr 95,000 MMP is regulated differently from that of interstitial collagenase, which is produced by the epithelial cells only in response to specific inductive factor(s) from the myoepithelial-like cells. Monoclonal antibodies raised against the purified latent Mr 95,000 form of the enzyme bind specifically to the Mr 95,000 MMP and have been used to localize the enzyme to the Golgi region and cytoplasmic granules of the epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1993164     DOI: 10.1021/bi00220a001

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

1.  Role of matrix metalloproteinases in failure to re-epithelialize after corneal injury.

Authors:  M E Fini; W C Parks; W B Rinehart; M T Girard; M Matsubara; J R Cook; J A West-Mays; P M Sadow; R E Burgeson; J J Jeffrey; M B Raizman; R R Krueger; J D Zieske
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

2.  Divergent patterns of matrix metalloproteinase activity during wound healing in ileum and colon of rats.

Authors:  W F Seifert; T Wobbes; T Hendriks
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

3.  Expression of 72 kDa and 92 kDa type IV collagenases from human giant-cell tumor of bone.

Authors:  V H Rao; J A Bridge; J R Neff; G B Schaefer; B A Buehler; J K Vishwanatha; R E Pollock; G L Nicolson; M Yamamoto; Z L Gokaslam
Journal:  Clin Exp Metastasis       Date:  1995-11       Impact factor: 5.150

4.  Circulating MMP-9 during exercise in humans.

Authors:  E Rullman; K Olsson; D Wågsäter; T Gustafsson
Journal:  Eur J Appl Physiol       Date:  2012-11-17       Impact factor: 3.078

5.  Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1.

Authors:  M Mohtai; R L Smith; D J Schurman; Y Tsuji; F M Torti; N I Hutchinson; W G Stetler-Stevenson; G I Goldberg
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

6.  Urine Peptidomic and Targeted Plasma Protein Analyses in the Diagnosis and Monitoring of Systemic Juvenile Idiopathic Arthritis.

Authors:  Xuefeng B Ling; Kenneth Lau; Chetan Deshpande; Jane L Park; Diana Milojevic; Claudia Macaubas; Chris Xiao; Viorica Lopez-Avila; John Kanegaye; Jane C Burns; Harvey Cohen; James Schilling; Elizabeth D Mellins
Journal:  Clin Proteomics       Date:  2010-09-30       Impact factor: 3.988

7.  Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells.

Authors:  Melanie Rolli; Emilia Fransvea; Jan Pilch; Alan Saven; Brunhilde Felding-Habermann
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-21       Impact factor: 11.205

Review 8.  Type IV collagenases in invasive tumors.

Authors:  K Tryggvason; M Höyhtyä; C Pyke
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

9.  Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells.

Authors:  T Morodomi; Y Ogata; Y Sasaguri; M Morimatsu; H Nagase
Journal:  Biochem J       Date:  1992-07-15       Impact factor: 3.857

10.  Walker 256 cancer cells secrete tissue inhibitor of metalloproteinase-free metalloproteinase-9.

Authors:  Maria Pavlaki; Eleftheria Giannopoulou; Anna Niarakis; Panagiota Ravazoula; Alexios J Aletras
Journal:  Mol Cell Biochem       Date:  2009-03-29       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.